These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 27170508)

  • 1. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments.
    Joosten LA; Abdollahi-Roodsaz S; Dinarello CA; O'Neill L; Netea MG
    Nat Rev Rheumatol; 2016 Jun; 12(6):344-57. PubMed ID: 27170508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs?
    Santegoets KC; van Bon L; van den Berg WB; Wenink MH; Radstake TR
    FEBS Lett; 2011 Dec; 585(23):3660-6. PubMed ID: 21513712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases?
    Beck C; Morbach H; Richl P; Stenzel M; Girschick HJ
    Rheumatol Int; 2009 Jan; 29(3):229-38. PubMed ID: 18821074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease.
    Mullen LM; Chamberlain G; Sacre S
    Arthritis Res Ther; 2015 May; 17(1):122. PubMed ID: 25975607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptors and NOD-like receptors in rheumatic diseases.
    McCormack WJ; Parker AE; O'Neill LA
    Arthritis Res Ther; 2009; 11(5):243. PubMed ID: 19835640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis.
    Drexler SK; Kong P; Inglis J; Williams RO; Garlanda C; Mantovani A; Yazdi AS; Brennan F; Feldmann M; Foxwell BM
    Arthritis Rheum; 2010 Aug; 62(8):2249-61. PubMed ID: 20506350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases.
    O'Neill LA
    Curr Opin Pharmacol; 2003 Aug; 3(4):396-403. PubMed ID: 12901949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in Toll-like receptor targeted therapeutics.
    Connolly DJ; O'Neill LA
    Curr Opin Pharmacol; 2012 Aug; 12(4):510-8. PubMed ID: 22748800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of toll-like receptors in chronic inflammation.
    Drexler SK; Foxwell BM
    Int J Biochem Cell Biol; 2010 Apr; 42(4):506-18. PubMed ID: 19837184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interleukin-1 receptor family.
    Boraschi D; Tagliabue A
    Semin Immunol; 2013 Dec; 25(6):394-407. PubMed ID: 24246227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis.
    Goh FG; Midwood KS
    Rheumatology (Oxford); 2012 Jan; 51(1):7-23. PubMed ID: 21984766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress.
    O'Neill LA
    Immunol Rev; 2008 Dec; 226():10-8. PubMed ID: 19161412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of Toll/Interleukin-1 Receptor (TIR) domain sequences from rhesus macaque Toll-like receptors (TLRs) 1-10 reveals high homology to human TLR/TIR sequences.
    Sanghavi SK; Shankarappa R; Reinhart TA
    Immunogenetics; 2004 Dec; 56(9):667-74. PubMed ID: 15578265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease.
    Clanchy FI; Sacre SM
    Expert Opin Biol Ther; 2010 Dec; 10(12):1703-16. PubMed ID: 21039312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the interleukin-1 family of ligands and receptors.
    Dinarello CA
    Semin Immunol; 2013 Dec; 25(6):389-93. PubMed ID: 24275600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammasomes and rheumatic diseases: evolving concepts.
    Sidiropoulos PI; Goulielmos G; Voloudakis GK; Petraki E; Boumpas DT
    Ann Rheum Dis; 2008 Oct; 67(10):1382-9. PubMed ID: 17921182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know?
    O'Neill LA
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):319-27. PubMed ID: 18446139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.
    Li J; Wang X; Zhang F; Yin H
    Pharmacol Ther; 2013 Jun; 138(3):441-51. PubMed ID: 23531543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptors in angiogenesis.
    Grote K; Schütt H; Schieffer B
    ScientificWorldJournal; 2011 Apr; 11():981-91. PubMed ID: 21516292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model.
    Sacre S; Lo A; Gregory B; Stephens M; Chamberlain G; Stott P; Brennan F
    Eur J Immunol; 2016 Mar; 46(3):772-81. PubMed ID: 26593270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.